Stroke:活性氧清除剂在急性脑出血患者中的疗效

2021-03-02 MedSci原创 MedSci原创

ROS清除剂显著降低了急性脑出血患者的PHE体积,并缩短了达到RASS镇静程度评估表目标值和重症监护病房住院的时间。在该研究中,早期和高剂量的ROS清除剂可能在获得良好结局中发挥了关键作用。

脑出血患者伴随着氧化应激增强。氧化应激有助于脑出血患者周围血肿的发生和发展。

近日,血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员推测活性氧簇(ROS)清除剂可能在脑出血患者急性期起神经保护作用。

这项前瞻性、多中心、单盲、随机研究于2017年6月至2019年10月期间进行。颅内出血包括自发性脑出血、血管异常、静脉血栓形成、肿瘤或出血性梗死引起的继发性脑出血。静脉给予活性氧清除剂n-乙酰半胱氨酸2000mg/d和硒1600µg/d,治疗14天。其他患者则接受安慰剂治疗。该研究的主要结局为ROS清除剂组与安慰剂组在随访2周时计算机断层扫描中出血和血肿周围水肿(PHE)体积的变化。

该研究总共纳入了448例患者,通过纳入和排除标准进行筛查后仍有123名患者。在ROS清除剂组(n=57)和安慰剂组(n=66)之间,患者基线特征没有显著差异。基线血肿和PHE体积无显著差异,但随访2周时计算机断层扫描风险PHE体积(21.90±17.63 vs 30.66±32.35,P<0.01)和PHE比值(1.19±0.73 vs 2.05±1.27,P<0.01)有显著差异。在众多临床因素中,相比于对照组,接受ROS清除剂治疗的患者达到RASS镇静程度评估表目标值的时间(5.98小时(95%CI为4.82-7.241和8.42小时(95%CI为6.57-10.77),P<0.01)和重症监护室停留长短(6.46天(95%CI为2.38-10.55和12.66天(95%CI为8.47-16.85),P<0.01)明显缩短。

由此可见,ROS清除剂显著降低了急性脑出血患者的PHE体积,并缩短了达到RASS镇静程度评估表目标值和重症监护病房住院的时间。在该研究中,早期和高剂量的ROS清除剂可能在获得良好结局中发挥了关键作用。

原始出处:

Moinay Kim.et al.Reactive Oxygen Species Scavenger in Acute Intracerebral Hemorrhage Patients
A Multicenter, Randomized Controlled Trial.stroke.2021.https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.032266

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1301387, encodeId=b7a6130138ebe, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu Mar 04 13:50:53 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945163, encodeId=ec7c9451634f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/14a81e233ddc44ebbd546a6376cdb33e/9b1eeca21f644ab4979394422ff645de.jpg, createdBy=b87d2058022, createdName=1851ed3e5dm, createdTime=Wed Mar 03 15:46:26 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945025, encodeId=7b19945025e0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Mar 03 07:26:04 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944989, encodeId=cd1394498970, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>活性氧, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e6d5462230, createdName=鼠叔叔啦啦, createdTime=Wed Mar 03 05:36:07 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032827, encodeId=6904103282e00, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 03 01:50:53 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-04 徐岩
  2. [GetPortalCommentsPageByObjectIdResponse(id=1301387, encodeId=b7a6130138ebe, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu Mar 04 13:50:53 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945163, encodeId=ec7c9451634f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/14a81e233ddc44ebbd546a6376cdb33e/9b1eeca21f644ab4979394422ff645de.jpg, createdBy=b87d2058022, createdName=1851ed3e5dm, createdTime=Wed Mar 03 15:46:26 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945025, encodeId=7b19945025e0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Mar 03 07:26:04 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944989, encodeId=cd1394498970, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>活性氧, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e6d5462230, createdName=鼠叔叔啦啦, createdTime=Wed Mar 03 05:36:07 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032827, encodeId=6904103282e00, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 03 01:50:53 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-03 1851ed3e5dm

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1301387, encodeId=b7a6130138ebe, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu Mar 04 13:50:53 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945163, encodeId=ec7c9451634f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/14a81e233ddc44ebbd546a6376cdb33e/9b1eeca21f644ab4979394422ff645de.jpg, createdBy=b87d2058022, createdName=1851ed3e5dm, createdTime=Wed Mar 03 15:46:26 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945025, encodeId=7b19945025e0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Mar 03 07:26:04 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944989, encodeId=cd1394498970, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>活性氧, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e6d5462230, createdName=鼠叔叔啦啦, createdTime=Wed Mar 03 05:36:07 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032827, encodeId=6904103282e00, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 03 01:50:53 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-03 学医无涯

    了解一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1301387, encodeId=b7a6130138ebe, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu Mar 04 13:50:53 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945163, encodeId=ec7c9451634f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/14a81e233ddc44ebbd546a6376cdb33e/9b1eeca21f644ab4979394422ff645de.jpg, createdBy=b87d2058022, createdName=1851ed3e5dm, createdTime=Wed Mar 03 15:46:26 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945025, encodeId=7b19945025e0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Mar 03 07:26:04 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944989, encodeId=cd1394498970, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>活性氧, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e6d5462230, createdName=鼠叔叔啦啦, createdTime=Wed Mar 03 05:36:07 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032827, encodeId=6904103282e00, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 03 01:50:53 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-03 鼠叔叔啦啦

    #学习#活性氧

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1301387, encodeId=b7a6130138ebe, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu Mar 04 13:50:53 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945163, encodeId=ec7c9451634f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/14a81e233ddc44ebbd546a6376cdb33e/9b1eeca21f644ab4979394422ff645de.jpg, createdBy=b87d2058022, createdName=1851ed3e5dm, createdTime=Wed Mar 03 15:46:26 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945025, encodeId=7b19945025e0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Mar 03 07:26:04 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944989, encodeId=cd1394498970, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>活性氧, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e6d5462230, createdName=鼠叔叔啦啦, createdTime=Wed Mar 03 05:36:07 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032827, encodeId=6904103282e00, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 03 01:50:53 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-03 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Clinica Chimica Acta:血浆骨桥蛋白是急性脑出血患者的预后指标?

骨桥蛋白(Osteopontin, OPN)是一种母体细胞蛋白,在急性脑损伤后的脑组织中可大量产生。本研究在一项临床研究中确定了急性脑出血(ICH)患者血浆OPN浓度与预后的关系。 在这个前瞻性观察研究中,研究人员招募了162例ICH患者和162名健康对照者,使用国立卫生研究院卒中量表(NIHSS)评分和血肿量评估了出血严重程度,不良预后定义为卒中后90天的改良Rankin量表≥2,而早期神

Stroke:平扫CT血肿扩大征象者可否使用止血药物?

急性脑出血(ICH)发病最初几个小时内,高达38%的患者会发生血肿扩大。不过,鉴于大部分 ICH 患者并未发生血肿扩大,识别处于血肿扩大风险的患者是非常重要的,比如在止血治疗的临床试验中有利于选择最有可能从止血治疗中获益的目标患者。

Clinica Chimica Acta:血清脂蛋白相关磷脂酶A2是一种有前景预后生物标志物,与急性脑出血90天的预后有关

脂蛋白相关磷脂酶A2 (Lp-PLA2)可反映血管炎症,在脑血管疾病的病理生理过程中起重要作用。我们确定血清Lp-PLA2作为脑出血(ICH)预后生物标志物的有效性。

2019 ESO指南:急性脑出血口服抗凝剂逆转

2019年12月,欧洲卒中组织(ESO)发布了急性脑出血口服抗凝剂逆转指南,文章主要针对急性脑出血冠状逆转口服抗凝剂提出了指导建议。

Clinica Chimica Acta:血液循环与急性脑出血的预后有关?

Klotho是一种抗衰老蛋白,其血浆浓度升高与急性缺血性脑卒中的良好功能预后有关。本研究旨在明确血浆Klotho在脑出血中的预后意义。

Stroke:急性脑出血患者生理评分异常与预后的关系

近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员旨在明确生理指标(收缩压、血糖和体温)异常和华法林使用与自发性脑出血患者预后之间的关系。